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Vaccines for Africa: a “limited market”?
African leaders are gathering in Addis Ababa, Ethiopia, 
this week for the ﬁ rst ever Ministerial Conference 
on Vaccines in Africa. The event brings together 
government oﬃ  cials, including minsters of ﬁ nance, 
technical experts, and policymakers, with the goal of 
advancing the coverage of life-saving immunisations 
across the continent.
There are many examples of highly successful African 
vaccination campaigns on which to base ongoing 
eﬀ orts. The most obvious recent campaign might be 
that against meningitis A: a disease that aﬀ ected a 
quarter of a million people in 1996, killing 25 000 of 
them. 20 years later, the disease is all but eliminated 
from Africa’s so-called meningitis belt—the 26 aﬀ ected 
countries spanning the continent from Senegal in the 
west to Ethiopia in the east. Since the introduction 
of a conjugate vaccine (PsA-TT; MenAfriVac) in 
2010, incidence has plummeted in all countries that 
have introduced it. In 2014 there were zero cases in 
vaccinated individuals. Work is continuing to ensure that 
these enormous gains—the result of well funded and 
externally organised mass vaccination campaigns—can 
be sustained by countries via their routine immunisation 
programmes. A special satellite meeting convened by 
the Meningitis Vaccine Project ahead of the ministerial 
conference aims to encourage and shape such plans.
The meningitis A story is unique in that it began 
not with the mere scale-up and aﬀ ordable supply of 
an existing vaccine, but with the creation of a low-
cost, bespoke vaccine speciﬁ cally for the region. Yet 
more conventional, long-running programmes have 
seen progress equally worth celebrating. As of Feb 3, 
Africa had gone 4 months without any circulating 
vaccine-derived cases of poliomyelitis or any positive 
environmental sample (and 18 months without a case 
of wild poliovirus)—the longest time in its history. 
One of the key aims of the ministerial conference this 
week is to reﬂ ect on the lessons that polio vaccination 
campaigns in Africa, particularly Nigeria, can oﬀ er to 
other health programmes such as those aiming to 
improve antenatal care, routine vaccination rates, 
screening for malnutrition, and health education. It 
would be a travesty if the tremendous eﬀ orts made in 
terms of political leadership, accountability, equitable 
access, and community engagement were to dry up as 
polio’s need for them recedes. This eﬀ ort to build on 
polio’s legacy is therefore a crucial one.
Further successes, highlighted in this journal, 
include the introduction into routine immunisation 
schedules of pentavalent rotavirus vaccine in Rwanda 
and Haemophilus inﬂ uenzae type b (Hib) vaccine 
in Kenya. These vaccines have led to substantial 
reductions in hospital admissions for non-bloody 
diarrhoea and invasive Hib disease, respectively. The 
need for continued surveillance is nevertheless critical, 
since waning immunity and adverse eﬀ ects (notably 
intussusception with rotavirus vaccine) are very 
real concerns.
Another particularly pressing concern is the alarming 
rise in an unusual strain of Neisseria meningitidis 
serogroup C in Africa over recent years. The unique clone 
is genetically distant from all other known C strains and 
only appeared in 2013, making it unlikely to have arisen 
as a result of serogroup replacement after meningitis 
A vaccination. 10 cases were conﬁ rmed in 2013, in 
Niger and Nigeria. However, numbers quickly rose 
to 48 conﬁ rmed cases in 2014, and 1196 in 2015. As 
many as 11 000 cases were suspected last year, of whom 
800 died. A shortage of vaccine hampered control 
eﬀ orts, prompting a multiagency warning about the 
potential for a much larger outbreak this year and a 
plea to vaccine manufacturers to expand stockpiles 
to 5 million by 2016. As we enter the 2016 meningitis 
season, the latest ﬁ gures up to January 24 show 
16 conﬁ rmed cases of meningitis C (13 in Niger, two in 
Ghana, and one in Burkina Faso) and only 4·2 million 
doses of vaccine available for the whole season, most of 
it only from March. WHO experts cite a “limited market” 
for the vaccine as a reason for the shortfall.
Again, we seem to be one step behind the microbes. 
In the case of the unprecedented explosion of Ebola and 
Zika viruses , the pharmaceutical industry’s failure to 
have a vaccine prepared could perhaps be understood. 
Yet in the case of N meningitidis, one serogroup of which 
caused very recent devastation and another of which is 
threatening to do the same, the industry’s stance seems 
shortsighted at best, and irresponsible at worst.
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